-
The annual increase of 357 stocks doubled, and pharmaceutical equipment companies performed well
Time of Update: 2022-01-24
According to the author's incomplete statistics, in the pharmaceutical and biological industry, there are at least 19 stocks with an annual increase of more than 100%, including Jiu'an Medical, Gongdong Medical, Boren Medical, Rejing Bio, Tuoxin Pharmaceutical, etc.
-
Local new drug research and development is facing this major challenge!
Time of Update: 2022-01-24
After multinational pharmaceutical companies have withdrawn from the domestic PD-1 promotion market, the track has become more and more crowded .
Up to now, a total of 12 PD-(L)1 products have been approved for marketing in China, of which 8 are domestic new drugs and 4 are imported drugs .
-
Pharmaceutical companies compete for the anti-tumor drug market, and innovative drugs become the key to development
Time of Update: 2022-01-24
It is understood that in recent years, with the support of a series of favorable policies, the innovation and research and development capabilities of domestic pharmaceutical companies for oncology drugs have been continuously improved, and they are already in a period of rapid growth .
-
The "ice-breaking" of the centralized procurement of Chinese patent medicine carries more expectations
Time of Update: 2022-01-24
Incorporating Chinese patent medicines into the scope of centralized drug procurement, thereby reversing the trend of price increases of Chinese patent medicines, is in line with the general expectations of the public .
-
Seven new drugs on track for approval and recent launch will be blockbuster treatments in the next five years
Time of Update: 2022-01-24
Yesterday, Mirati's executives announced at the JPM conference report that the company had submitted a new drug application for adagrasib to the US FDA at the end of last year for the second-line treatment of patients with non-small cell lung cancer carrying the KRAS G12C mutation .
-
Pfizer reached four collaborations in two days involving AI pharmaceuticals, in vivo gene editing, etc.
Time of Update: 2022-01-24
Join hands with Beam to develop in vivo base editing therapyOn January 10, Pfizer announced an exclusive four-year research collaboration agreement with Beam Therapeutics .
As part of the collaboration, the efficacy of the developed base editing program will be assessed by delivery to target organs using Beam's proprietary in vivo delivery technology .
-
The State Food and Drug Administration cancelled the drug registration certificate of Lianbizhi injection!
Time of Update: 2022-01-23
After evaluation, the State Drug Administration decided to stop the production, sales and use of Lianbizhi injection in China from now on, and cancel the drug registration certificate .
-
Pharmaceutical companies disclosed 2021 performance reports, a company's net profit increased by more than 30%
Time of Update: 2022-01-23
According to the 2021 annual performance forecast announced by Huaren Pharmaceutical, it is estimated that in 2021, its net profit attributable to shareholders of listed companies will be 125 million yuan to 150 million yuan, a year-on-year increase of 32.
-
9 pharmaceutical companies have changed their executives within two weeks!
Time of Update: 2022-01-23
On January 3, Huahai Pharmaceutical issued an announcement stating that the board of directors recently received the resignation document of Wang Jie, the vice president of the company.
-
Innovation has become the core competitiveness of traditional Chinese medicine, and a large number of new traditional Chinese medicine drugs will emerge one after another
Time of Update: 2022-01-23
At the same time, the series of pharmacological and toxicological studies and clinical trial data of Qirui Weishu Capsules show that the drug has a significant effect in the treatment of chronic non-atrophic gastritis with erosion and damp-heat stasis syndrome, especially in improving epigastric pain and TCM syndromes.
-
TIGIT targets have become the focus of many pharmaceutical companies, and R&D and cooperation are increasing day by day
Time of Update: 2022-01-23
The industry believes that after Novartis received BeiGene's PD-1, it has to start with the latter's TIGIT monoclonal antibody, mainly because large pharmaceutical companies are now scanning TIGIT antibodies, and Novartis' own product pipeline does not have TIGIT antibodies.
-
Chinese medicine has become a "sweet pastry"!
Time of Update: 2022-01-23
On December 14, 23 and 27, 2021, Jiuzhitang said in an institutional survey that "the raw materials of traditional Chinese medicine are affected by climate, planting area and other factors, and there is a general price increase", and the company also stated that it will "comprehensively consider cost changes.
-
Within a week, the pharmaceutical company has received research from more than 340 institutions
Time of Update: 2022-01-23
Then on the 10th, Huadong Medicine issued another announcement saying: Huatai Pineapple, Toroa Management, Industrial Securities, Bank of Communications Schroders Fund, Ping An Asset, GF Fund, Nanhua Fund, Huisheng Fund, BlackRock Fund, Sequoia Capital , Guotai Junan Asset Management, Jiahe Fund, Minsheng Jiayin Fund, Qianhai United Fund, Guolian Fund, Taikang Assets and other 40 institutions investigated our company on January 7, 2022 .
-
EU approves Novo Nordisk's GLP-1 agonist Wegovy to treat obesity
Time of Update: 2022-01-22
The approval of Wegovy, an unprecedented weight loss product, marks a new era in the treatment of obesity, a chronic disease that requires long-term treatment and is associated with many serious health consequences and reduced life expectancy .
-
Rheumatism drug baricitinib has been recommended by WHO for severe patients with new crown and has been listed in China
Time of Update: 2022-01-22
It is understood that baricitinib is a tyrosine protein kinase (JAK) 1/2 inhibitor discovered by Incyte and licensed to Eli Lilly, which was originally used for one or more disease-modifying antirheumatic drugs ( DMARDs) can be used in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs for the treatment of adults with moderately to severely active rheumatoid arthritis who are ineffective or intolerable .
-
Do small and medium-sized chain pharmacies sell them?
Time of Update: 2022-01-22
If you are the owner of a small and medium-sized pharmacy chain, and a leading company wants to acquire your store, will you sell it?
-
In 2022, small and medium-sized pharmacies will still be eliminated or acquired at an accelerated pace
Time of Update: 2022-01-22
In this regard, the industry generally believes that with the help of this policy, the competition in the pharmaceutical retail market will become more intense in the future, the trend of expansion of large chain pharmacies will continue to accelerate, and more small and medium-sized pharmacies in the industry will also be accelerated.
-
The scale of the CRO market continues to expand, and a large number of companies will achieve a year-on-year increase in net profit
Time of Update: 2022-01-22
The announcement shows that Tigermed's expected 2021 revenue and net profit attributable to shareholders of listed companies have increased compared with the same period last year .
-
The domestic market share of high-end medical equipment is less than 20%, and there is a lot of room for import substitution in the future
Time of Update: 2022-01-22
With the support of favorable policies, it will stimulate the enthusiasm for R&D and manufacturing of domestic equipment enterprises, help the entire industry to accelerate the transformation towards intelligent manufacturing, and release new vitality in the market .
-
How will the pharmaceutical sector perform in 2022?
Time of Update: 2022-01-22
For example, when the industrial indexes such as medical devices, chemical drugs, biological products, and medical services have fallen, traditional Chinese medicine has risen against the trend .
